Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$567.14M
EPS-1.3500
P/E Ratio-2.33
Earnings Date08/06/2026

prme

Capital Lease Obligations

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Capital Lease Obligations

PRME · NASDAQ
CompanyCapital Lease Obligations
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
2.96M
-12.4%17.3%N/A
9.47M
6.4%6.6%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
0.00
N/AN/AN/A
20.77M
61.8%51.0%N/A
29.79M
-2.5%-2.2%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
1.61M
-13.3%29.0%52.9%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
89.05M
-10.6%-8.3%N/A
0.00
N/AN/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.14